AddLife (ALIF B.ST) Akcija Kursas
AddLife Kursas
Pajamos augo 20,7 % per metus per pastaruosius 13 metus iki 10,44 mlrd. SEK. Pelnas akcijai augo 16,9 % per metus per pastaruosius 13 metus. AddLife grynoji marža dabar yra 5,4 %, sumažėjo nuo 9,0 % prieš kelerius metus. AddLife šiuo metu siūlo apie 0,44 % dividendo pajamingumą. Išmokų koeficientas yra apie 16 % pelno. Dividendas augo 9,1 % per metus per pastaruosius 8 metus. Analitikų tikslinės kainos mediana yra 218,28 SEK, t. y. virš dabartinę kainą 29,2 %. Iš 8 analitikų 5 rekomenduoja pirkti — bendras konsensusas yra Pirkti.
AddLife akcijos kaina
AddLife akcija ir akcijų analizė
Dažnai užduodami klausimai apie AddLife akciją
The business model of AddLife AB revolves around the distribution and marketing of high-quality products and services within the life science sector. AddLife AB primarily focuses on three business areas: Labtech, Medtech, and Diagnostics. Labtech involves offering innovative solutions, including equipment and consumables, to laboratories and research institutions. Medtech includes the distribution of medical technology products for healthcare and rehabilitation. Diagnostics encompasses the supply of diagnostic products and services for medical laboratories. AddLife AB aims to provide its customers with comprehensive solutions, strong expertise, and reliable deliveries to meet their needs in the life science industry.
AddLife AB is primarily active in the industries of life sciences and healthcare.
The main competitors of AddLife AB in the market are its industry peers, such as Getinge AB, Lifco AB, and Elekta AB.
AddLife AB is a Swedish company specializing in the distribution and sales of high-quality products for the healthcare sector. Founded in 2016, AddLife has quickly become a leading player in the Nordic region, providing services and solutions within the fields of laboratory equipment, diagnostics, and biotechnology. The company focuses on areas such as research, healthcare, and life science, offering a wide range of products from renowned global manufacturers. With its extensive expertise and strong market presence, AddLife continues to evolve and expand its operations, driving advancements in healthcare and contributing to the well-being of individuals and society as a whole.
AddLife AB, a leading company in the life science sector, has achieved several notable milestones. The company has successfully expanded its presence and market share, becoming a key player in the industry. AddLife AB has made strategic acquisitions, enhancing its product portfolio and geographical reach. Additionally, it has formed collaborations with renowned partners, reinforcing its position as an innovative and reliable partner in the life science field. The company's steadfast commitment to customer satisfaction and focus on delivering high-quality products and services have contributed to its continued success and growth. AddLife AB's dedication to excellence has led to significant achievements and recognition within the life science industry.
AddLife AB is primarily present in Sweden and Finland.
AddLife AB is a leading company that represents strong values and a robust corporate philosophy. They prioritize customer satisfaction and strive to deliver exceptional products and services. AddLife AB values integrity, professionalism, and continuous improvement in everything they do. With a focus on innovation and sustainability, the company aims to create long-term value for both stakeholders and society as a whole. By providing high-quality healthcare solutions and fostering partnerships, AddLife AB demonstrates their commitment to improving people's lives.
Analitikai šiuo metu nustato vidutinę AddLife akcijos tikslinę kainą 208,59 SEK (mediana: 218,28 SEK), t. y. +23,4 % palyginti su paskutine kaina. Konsensusas pagrįstas 8 analitikų reitingais.
8 analitikai šiuo metu vertina AddLife akciją: 5 rekomenduoja pirkti, 3 laikyti ir 0 parduoti. 2026 m. analitikai tikisi, kad AddLife gaus 10,90 mlrd. SEK pajamų ir 6,28 SEK pelno akcijai.
Pagal dabartinį kursą AddLife akcija kainuoja 15,10 EUR (169,00 SEK).
AddLife akcija (ALIF B.ST) kotiruojama 6 biržose, įskaitant: London (0REZ.L), Frankfurt (1AD1.F), München (1AD1.MU), Stockholm (ALIF B.ST).
The Swedish company AddLife AB is a B2B company that offers products and solutions for the healthcare sector. The company focuses on four main business areas: Life Science, Labtech, Medtech, and Healthcare. AddLife offers its customers a wide range of products, services, and solutions in these areas. In the Life Science area, AddLife offers products and solutions for the research and development of pharmaceutical and biotechnology companies. This includes, for example, analysis instruments, laboratory equipment and chemicals, as well as consumables. The Labtech area specializes in laboratory equipment. This includes, for example, workstations, technical systems, and consumables. Software solutions for the execution and evaluation of experiments are also part of the offer. In the Medtech area, AddLife offers products and solutions for diagnostics and therapy. This includes, for example, instruments for cardiology or laboratory medicine, as well as consumables for medical examinations. Special products for infection control are also offered. In the Healthcare area, AddLife offers products and solutions for nursing and rehabilitation. This includes, for example, aids for mobility promotion, products for wound care or incontinence care. AddLife does not sell its products and solutions directly to end customers, but to companies and institutions in the healthcare sector such as hospitals, practices, or research institutes. AddLife follows a clear strategy to expand and develop its business. This includes, for example, acquisitions, cooperations, and networking. This way, AddLife can expand its product portfolio and use the expertise of its partners. The internationalization of the business also plays an important role. AddLife is already active in several countries worldwide and plans to further expand its business. The business model of AddLife is based on long-term customer relationships and a high quality of products and services. AddLife works closely with its customers and offers them customized solutions. Customers can benefit from the extensive experience and expertise of AddLife. In summary, AddLife is an innovative and future-oriented company that offers products and solutions for the healthcare sector. Through its clear strategy, high quality products and services, and collaboration with partners and customers, AddLife aims to further expand its business and strengthen its position in the market.
tikėtina pelnas AddLife yra 10,90 mlrd. SEK. Šis skaičius grindžiamas dabartiniais finansiniais duomenimis ir atspindi įmonės verslo rezultatus.
tikėtina grynasis pelnas AddLife yra 765,18 mln. SEK. Grynasis pelnas atspindi įmonės pelningumą po visų išlaidų atimties.
Kainų ir nuomos santykis (KGV) AddLife šiuo metu yra 26,92. KGV lygina dabartinę akcijos kainą su pelnu už akciją ir padeda investuotojams įvertinti AddLife akcijos vertę.
Kainų ir pardavimų santykis (KUV) AddLife šiuo metu yra 1,89. KUV lygina rinkos kapitalizaciją su metinėmis pajamomis ir yra AddLife akcijos įvertinimo metrika.
Eulerpool kokybės balas AddLife yra 5/10.
AddLife ISIN yra SE0014401378. ISIN (International Securities Identification Number) yra pasaulinė unikali vertybinių popierių identifikacijos sistema.
AddLife WKN yra A2P4TH. WKN (Wertpapierkennnummer) yra šešiaženklė vokiška vertybinių popierių identifikacijos sistema.
AddLife prekybos žymė yra ALIF B.ST. Ši biržos žymė naudojama AddLife akcijoms prekiauti biržoje.
AddLife akcija
AddLife Pagrindiniai konkurentai
AddLife Biržos simbolis
AddLife FIGI
Visos AddLife pagrindinės charakteristikos ir giluminė analizė
Mūsų akcijų analizė AddLife akcijai apima svarbius finansinius rodiklius, tokius kaip apyvarta, pelnas, P/E santykis, P/S santykis, EBIT, taip pat informaciją apie dividendes. Be to, mes nagrinėjame aspektus, tokius kaip akcijos, rinkos kapitalizacija, skolos, nuosavas kapitalas ir įsipareigojimai AddLife. Jei ieškote išsamesnės informacijos šiais klausimais, mūsų poskyriuose galite rasti išsamias analizes: